Advertisement
Australia markets open in 5 hours 44 minutes
  • ALL ORDS

    8,076.90
    +101.80 (+1.28%)
     
  • AUD/USD

    0.6649
    -0.0009 (-0.14%)
     
  • ASX 200

    7,838.80
    +105.10 (+1.36%)
     
  • OIL

    81.05
    -0.58 (-0.71%)
     
  • GOLD

    2,329.70
    -14.70 (-0.63%)
     
  • Bitcoin AUD

    92,116.03
    +1,789.75 (+1.98%)
     
  • CMC Crypto 200

    1,275.90
    +26.78 (+2.14%)
     

Twist Bioscience to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 23, 2024--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will present and participate in fireside chats at the following upcoming investor conferences:

  • Patrick Finn, Ph.D., president and COO, will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, in Austin, TX; fireside chat at 2:20 p.m. Central Time

  • Emily Leproust, Ph.D., CEO and co-founder, will present at the William Blair Growth Stock Conference on Tuesday, June 4 in Chicago, IL; presentation at 2:40 p.m. Central Time

  • Emily Leproust, Ph.D., CEO and co-founder, will present at the Jefferies Global Healthcare Conference on Thursday, June 6 in New York, NY; presentation at 8:30 a.m. Eastern Time

  • Emily Leproust, Ph.D., CEO and co-founder, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11 in Miami, FL; fireside chat at 10:00 a.m. Eastern Time

The fireside chats and presentations will be webcast live and can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website here. A replay of the fireside chats and presentations will be archived for a period of 30 days following the conclusion of the live events.

ADVERTISEMENT

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on LinkedIn | X | YouTube | Instagram

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523995309/en/

Contacts

For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com

For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com